LB
Therapeutic Areas
atai Life Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PCN-101 (R-ketamine) | Treatment-Resistant Depression (TRD) | Phase 2 |
| RL-007 | Cognitive Impairment Associated with Schizophrenia (CIAS) | Phase 2 |
| DMX-1002 (Ibogaine) | Opioid Use Disorder (OUD) | Phase 1/2a |
| GRX-917 (Deuterated Etifoxine) | Generalized Anxiety Disorder (GAD) | Phase 1 |
| VLS-01 (DMT) | Treatment-Resistant Depression (TRD) | Phase 1 |
| EMP-01 (MDMA derivative) | Post-Traumatic Stress Disorder (PTSD) | Preclinical |
| KUR-101 (Deuterated Mitragynine) | Opioid Use Disorder (OUD) | Preclinical |
| Salvianolic Acid B | Treatment-Resistant Depression (TRD) | Preclinical |
Leadership Team at atai Life Sciences
FB
Florian Brand
Co-Founder & Chief Executive Officer
SB
Stephen Bardin
Chief Financial Officer
SR
Srinivas Rao
Co-Founder & Chief Scientific Officer
MA
Michael Andree
Chief Operating Officer
GW
Gregory Weaver
Chief Financial Officer (former)
AS
Andrea Spezzi
Chief Marketing Officer & Head of Digital
CA
Christian Angermayer
Co-Founder & Chairman of the Board
SK
Sahil Kirpekar
Board Member
EA
Ernest A. Bates, M.D.
Board Member
JC
Jason C. Bartz, Ph.D.
Board Member, Scientific Advisory Board Chair